Saibal Kar, Raj R Makkar, Brian K Whisenant, Nadira Hamid, Hursh Naik, Peter Tadros, Matthew J Price, Gagan Singh, Jonathan G Schwartz, Samir Kapadia, Oluseun Alli, Samuel Horr, Puvi Seshiah, Wayne Batchelor, Brandon M Jones, Mustafa I Ahmed, Raymond Benza, Ulrich Jorde, Vinod H Thourani, Andrew A Ghobrial, Gilbert H L Tang, Phillip M Trusty, Dina Huang, Rebecca T Hahn, David H Adams, Paul Sorajja
{"title":"Two-year Outcomes of Transcatheter Edge-to-edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Trial.","authors":"Saibal Kar, Raj R Makkar, Brian K Whisenant, Nadira Hamid, Hursh Naik, Peter Tadros, Matthew J Price, Gagan Singh, Jonathan G Schwartz, Samir Kapadia, Oluseun Alli, Samuel Horr, Puvi Seshiah, Wayne Batchelor, Brandon M Jones, Mustafa I Ahmed, Raymond Benza, Ulrich Jorde, Vinod H Thourani, Andrew A Ghobrial, Gilbert H L Tang, Phillip M Trusty, Dina Huang, Rebecca T Hahn, David H Adams, Paul Sorajja","doi":"10.1161/CIRCULATIONAHA.125.074536","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>One-year outcomes of the TRILUMINATE Pivotal trial found that transcatheter edge-to-edge repair (TEER) for the treatment of severe, symptomatic tricuspid regurgitation (TR) improved quality-of-life compared with medical therapy alone with similar rates of mortality and heart failure hospitalization (HFH). However, additional follow-up is necessary to determine prolonged benefits of tricuspid TEER.</p><p><strong>Methods: </strong>A total of 572 patients with severe, symptomatic TR were randomized to either tricuspid TEER+medical therapy (Device) or medical therapy alone (Control). Two-year prespecified endpoints were (1) recurrent HFH and (2) freedom from all-cause mortality, tricuspid valve surgery and tricuspid valve intervention post treatment visit, assessed in the intention-to-treat population.</p><p><strong>Results: </strong>The annualized rate of recurrent heart failure hospitalizations through 2 years was significantly lower with tricuspid TEER compared with Control (0.19 vs 0.26 events/patient-year, p=0.02; joint frailty model hazard ratio 0.72, one-sided upper confidence limit of 0.93, p=0.02). Freedom from all-cause mortality, tricuspid valve surgery, and tricuspid valve intervention through 2 years was significantly higher with tricuspid TEER compared with Control (77.6% vs 29.3%, p<0.0001) driven by more tricuspid valve intervention in control patients crossing over to device treatment (3.8% vs. 61.5%). Rates of all-cause mortality (17.9% vs. 17.1%) and tricuspid valve surgery (2.3% vs. 4.3%) were similar between groups. Moderate-or-less TR was present in 84% at 2 years in the Device group.</p><p><strong>Conclusions: </strong>At 2-year follow-up, tricuspid TEER appears safe, significantly reduced TR severity, and decreased rates of HFH compared with medical therapy alone.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":35.5000,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1161/CIRCULATIONAHA.125.074536","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: One-year outcomes of the TRILUMINATE Pivotal trial found that transcatheter edge-to-edge repair (TEER) for the treatment of severe, symptomatic tricuspid regurgitation (TR) improved quality-of-life compared with medical therapy alone with similar rates of mortality and heart failure hospitalization (HFH). However, additional follow-up is necessary to determine prolonged benefits of tricuspid TEER.
Methods: A total of 572 patients with severe, symptomatic TR were randomized to either tricuspid TEER+medical therapy (Device) or medical therapy alone (Control). Two-year prespecified endpoints were (1) recurrent HFH and (2) freedom from all-cause mortality, tricuspid valve surgery and tricuspid valve intervention post treatment visit, assessed in the intention-to-treat population.
Results: The annualized rate of recurrent heart failure hospitalizations through 2 years was significantly lower with tricuspid TEER compared with Control (0.19 vs 0.26 events/patient-year, p=0.02; joint frailty model hazard ratio 0.72, one-sided upper confidence limit of 0.93, p=0.02). Freedom from all-cause mortality, tricuspid valve surgery, and tricuspid valve intervention through 2 years was significantly higher with tricuspid TEER compared with Control (77.6% vs 29.3%, p<0.0001) driven by more tricuspid valve intervention in control patients crossing over to device treatment (3.8% vs. 61.5%). Rates of all-cause mortality (17.9% vs. 17.1%) and tricuspid valve surgery (2.3% vs. 4.3%) were similar between groups. Moderate-or-less TR was present in 84% at 2 years in the Device group.
Conclusions: At 2-year follow-up, tricuspid TEER appears safe, significantly reduced TR severity, and decreased rates of HFH compared with medical therapy alone.
背景:TRILUMINATE枢纽试验的一年结果发现,与单纯药物治疗相比,经导管边缘到边缘修复(TEER)治疗严重症状性三尖瓣反流(TR)改善了生活质量,死亡率和心力衰竭住院率(HFH)相似。然而,需要额外的随访来确定三尖瓣TEER的长期益处。方法:将572例重度症状性TR患者随机分为三尖瓣TEER+药物治疗组(Device)和单纯药物治疗组(Control)。两年的预定终点是(1)复发性HFH和(2)无全因死亡率、三尖瓣手术和治疗后三尖瓣干预,在意向治疗人群中进行评估。结果:与对照组相比,三尖瓣TEER组2年内心力衰竭复发的年化住院率显著降低(0.19 vs 0.26事件/患者年,p=0.02;关节脆弱模型风险比0.72,单侧置信上限0.93,p=0.02)。与对照组相比,三尖瓣TEER组2年内无全因死亡率、三尖瓣手术和三尖瓣干预的发生率显著高于对照组(77.6% vs 29.3%)。结论:在2年随访中,三尖瓣TEER是安全的,显著降低了TR严重程度,与单纯药物治疗相比,HFH发生率降低。
期刊介绍:
Circulation is a platform that publishes a diverse range of content related to cardiovascular health and disease. This includes original research manuscripts, review articles, and other contributions spanning observational studies, clinical trials, epidemiology, health services, outcomes studies, and advancements in basic and translational research. The journal serves as a vital resource for professionals and researchers in the field of cardiovascular health, providing a comprehensive platform for disseminating knowledge and fostering advancements in the understanding and management of cardiovascular issues.